GLP-1s reshape obesity care as use rises, persistence and cost remain key questions

As World Obesity Day spotlights rising obesity rates, GLP-1s reshape treatment and coverage debates, with persistence, affordability and long-term value driving payer decisions.

Most days, including World Obesity Day, the conversations around weight management have been much different than they were just a few years ago. Obesity rates remain high, but new data suggests injectable glucagon-like peptide-1 (GLP-1) drugs are beginning to influence both clinical practice and utilization trends across the healthcare system.